PD-1 immunotherapy in pancreatic cancer: current status
Abstract. Pancreatic ductal adenocarcinoma is the known kind of tumor biologically featured as high malignant degree, lack of effective methods for diagnosis and treatment, which reflects its unpleasant prognosis. Recently, with the breakthrough of burgeoning therapeutic methods, the flush of dawn f...
| Main Authors: | , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wolters Kluwer Health/LWW
2019-03-01
|
| Series: | Journal of Pancreatology |
| Online Access: | http://journals.lww.com/10.1097/JP9.0000000000000010 |
| _version_ | 1819137519325806592 |
|---|---|
| author | Ning Pu, MD Wenhui Lou, MD, PhD Jun Yu, MD, PhD |
| author_facet | Ning Pu, MD Wenhui Lou, MD, PhD Jun Yu, MD, PhD |
| author_sort | Ning Pu, MD |
| collection | DOAJ |
| description | Abstract. Pancreatic ductal adenocarcinoma is the known kind of tumor biologically featured as high malignant degree, lack of effective methods for diagnosis and treatment, which reflects its unpleasant prognosis. Recently, with the breakthrough of burgeoning therapeutic methods, the flush of dawn for pancreatic cancer nearly arrives. Nowadays, besides surgery, neoadjuvant chemoradiotherapy, tumor vaccine therapy, and immunotherapy all show their active situation and obtain certain clinical efficacy, but that is still limited to pancreatic cancer. However, the appearance and development of programmed cell death-1 (PD-1) immune checkpoint inhibitor may final improve survival of pancreatic cancer. This article aims to deeply understand the value of PD-1 immune checkpoint inhibitor in pancreatic cancer and validly provide the evidence for treatment by means of performing a systematic review on the current status in the fields of the mechanism and application of anti-PD-1 in pancreatic cancer, associations with surgery, PD-1-related side effects and prospections. |
| first_indexed | 2024-12-22T10:52:10Z |
| format | Article |
| id | doaj.art-805210008be64f0594d9d9d5016ba7f4 |
| institution | Directory Open Access Journal |
| issn | 2096-5664 2577-3577 |
| language | English |
| last_indexed | 2024-12-22T10:52:10Z |
| publishDate | 2019-03-01 |
| publisher | Wolters Kluwer Health/LWW |
| record_format | Article |
| series | Journal of Pancreatology |
| spelling | doaj.art-805210008be64f0594d9d9d5016ba7f42022-12-21T18:28:44ZengWolters Kluwer Health/LWWJournal of Pancreatology2096-56642577-35772019-03-012161010.1097/JP9.0000000000000010201903000-00002PD-1 immunotherapy in pancreatic cancer: current statusNing Pu, MDWenhui Lou, MD, PhDJun Yu, MD, PhDAbstract. Pancreatic ductal adenocarcinoma is the known kind of tumor biologically featured as high malignant degree, lack of effective methods for diagnosis and treatment, which reflects its unpleasant prognosis. Recently, with the breakthrough of burgeoning therapeutic methods, the flush of dawn for pancreatic cancer nearly arrives. Nowadays, besides surgery, neoadjuvant chemoradiotherapy, tumor vaccine therapy, and immunotherapy all show their active situation and obtain certain clinical efficacy, but that is still limited to pancreatic cancer. However, the appearance and development of programmed cell death-1 (PD-1) immune checkpoint inhibitor may final improve survival of pancreatic cancer. This article aims to deeply understand the value of PD-1 immune checkpoint inhibitor in pancreatic cancer and validly provide the evidence for treatment by means of performing a systematic review on the current status in the fields of the mechanism and application of anti-PD-1 in pancreatic cancer, associations with surgery, PD-1-related side effects and prospections.http://journals.lww.com/10.1097/JP9.0000000000000010 |
| spellingShingle | Ning Pu, MD Wenhui Lou, MD, PhD Jun Yu, MD, PhD PD-1 immunotherapy in pancreatic cancer: current status Journal of Pancreatology |
| title | PD-1 immunotherapy in pancreatic cancer: current status |
| title_full | PD-1 immunotherapy in pancreatic cancer: current status |
| title_fullStr | PD-1 immunotherapy in pancreatic cancer: current status |
| title_full_unstemmed | PD-1 immunotherapy in pancreatic cancer: current status |
| title_short | PD-1 immunotherapy in pancreatic cancer: current status |
| title_sort | pd 1 immunotherapy in pancreatic cancer current status |
| url | http://journals.lww.com/10.1097/JP9.0000000000000010 |
| work_keys_str_mv | AT ningpumd pd1immunotherapyinpancreaticcancercurrentstatus AT wenhuiloumdphd pd1immunotherapyinpancreaticcancercurrentstatus AT junyumdphd pd1immunotherapyinpancreaticcancercurrentstatus |